Table 2.
The significant KEGG pathways enrichment analysis. The corrected p was calculated using Benjamini and Hochberg’s (1995) method.
| Term | Input | Background | p | Coreected p2 | Genes |
|---|---|---|---|---|---|
| Metabolic pathways | 21 | 1433 | 1.92 × 10−05 | 2.39 × 10−03 | NDUFAB1, ATP6V1D, EXTL3, etc. |
| Cell cycle | 6 | 124 | 5.73 × 10−05 | 4.48 × 10−03 | CCNB2, BUB1B, PLK1, etc. |
| Thermogenesis | 7 | 231 | 2.34 × 10−04 | 1.35 × 10−02 | NDUFAB1, LIPE, BMP8A, etc. |
| Human papillomavirus infection | 8 | 330 | 3.67 × 10−04 | 2.05 × 10−02 | ATP6V1D, HEYL, MAGI1, etc. |
| Huntington’s disease | 6 | 193 | 5.75 × 10−04 | 2.42 × 10−02 | NDUFAB1, DNAH3, ATP5A1, etc. |
| Proteoglycans in cancer | 6 | 203 | 7.43 × 10−04 | 2.52 × 10−02 | CD44, CDKN1A, ANK2, etc. |
| Cushing’s syndrome | 5 | 155 | 1.42 × 10−03 | 3.76 × 10−02 | AHR, WNT16, CDKN1A, etc. |
| Taurine and hypotaurine metabolism | 2 | 11 | 1.94 × 10−03 | 4.18 × 10−02 | GGT1, GGT5 |